UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063663
Receipt number R000072859
Scientific Title Establishment of a non-invasive remote screening system for lower extremity artery disease (LEAD) in patients on dialysis: a diagnostic accuracy study of multimodal remote assessment complementing the limitations of the ankle-brachial index (ABI)
Date of disclosure of the study information 2026/11/17
Last modified on 2026/11/17 09:48:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility of remote detection of leg artery disease by vascular specialists in people on dialysis, using foot photographs and simple test results collected at dialysis facilities

Acronym

A Study on Remote LEAD Screening for Dialysis Patients

Scientific Title

Establishment of a non-invasive remote screening system for lower extremity artery disease (LEAD) in patients on dialysis: a diagnostic accuracy study of multimodal remote assessment complementing the limitations of the ankle-brachial index (ABI)

Scientific Title:Acronym

A Study on Remote LEAD Screening for Dialysis Patients

Region

Japan


Condition

Condition

Lower extremity artery disease (LEAD) in patients on maintenance dialysis

Classification by specialty

Nephrology Vascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate, in routine dialysis settings, the feasibility of a remote screening system (Steplife) in which vascular specialists asynchronously assess simple data collected by non-specialist staff at dialysis facilities (photographs of the feet, arterial pulse palpation, photographs of Doppler waveforms, and symptoms).
Specifically, to determine the proportion of patients for whom the specialists could reach a remote judgement (judgeability rate), the proportion judged positive for suspected LEAD or ischemia (remote positive rate), and the acquisition rate of each data item collected at the facilities. In addition, disease status is assigned by a predefined composite reference standard, and sensitivity and specificity are calculated as secondary outcomes.

Basic objectives2

Others

Basic objectives -Others

Feasibility and diagnostic accuracy

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Positive and Negative Predictive Values for Telemedical Screening: The proportion of cases among all registered cases that received a final positive or negative determination (point estimate and 95% confidence interval). The evaluation period spans from data entry at the case-registering institution (baseline) until the completion of the telemedical evaluation by a specialist (cases for which a final determination is not confirmed within 14 days of the telemedical evaluation request being entered into the system are classified as "pending").

Key secondary outcomes

1. Remote positive rate and referral rate (proportion of patients referred to a specialist institution by the attending physician within 90 days of the index date, i.e., the date the data for judgement were obtained)
2. Acquisition rate of each data item (foot photographs, arterial palpation, Doppler waveform images)
3. Inter-rater agreement between the two evaluators (kappa coefficient)
4. Reasons for indeterminate judgements
5. Agreement between facility staff and evaluators in Doppler waveform classification (weighted kappa coefficient)
6. Time to judgement (from case submission to final judgement)
7. Consent rate
8. Sensitivity and specificity against the composite reference standard (established diagnosis at the index date, results of examinations at specialist institutions within 90 days, and clinical course over 90 days)
9. Number and proportion of additional detections among patients with a negative ABI (negative defined as ABI >0.7 and, separately, as ABI >=0.9)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Other

Interventions/Control_1

Staff at the dialysis facility take photographs of the feet, palpate the dorsalis pedis and posterior tibial arteries, record and briefly classify Doppler waveforms with a portable Doppler device, and ask about symptoms; these data are entered into the remote screening system (Steplife). Two vascular specialists who are not involved in the patient's care independently review the data and judge whether LEAD or ischemia is suspected (positive, negative, or indeterminate); if the two disagree, an adjudicator (another vascular specialist) makes the final judgement. The evaluators are blinded to the results of reference standard examinations, ABI values, and subsequent outcomes. The judgement is returned to the attending physician, who decides on referral as part of routine care. Data are collected once at baseline, and the clinical course over the following 90 days is collected from medical records. No examination corresponding to the reference standard (contrast CT, angiography, SPP, TBI) is newly performed for research purposes.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients on maintenance dialysis aged 18 years or older at the time of consent who attend a participating facility during the enrollment period
2. Patients who have given written informed consent to participate in this study

Key exclusion criteria

1. Patients in a serious general condition whom the principal investigator at the participating site considers difficult to evaluate in this study
2. Patients for whom the principal investigator at the participating site considers it difficult to give consent themselves because of cognitive decline or other reasons

Target sample size

90


Research contact person

Name of lead principal investigator

1st name Shinya
Middle name
Last name Takase

Organization

Fukushima Medical University, School of Medicine

Division name

Department of Advanced Integrated Angiology

Zip code

9601295

Address

1 Hikarigaoka, Fukushima City, Fukushima

TEL

0245471281

Email

s-takase@fmu.ac.jp


Public contact

Name of contact person

1st name Shinya
Middle name
Last name Takase

Organization

Fukushima Medical University, School of Medicine

Division name

Department of Advanced Integrated Angiology

Zip code

9601295

Address

1 Hikarigaoka, Fukushima City, Fukushima

TEL

0245471281

Homepage URL


Email

s-takase@fmu.ac.jp


Sponsor or person

Institute

Fukushima Medical University, School of Medicine

Institute

Department

Personal name



Funding Source

Organization

SECOND HEART Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor

SECOND HEART Inc.

Name of secondary funder(s)

Fukushima Prefecture, FY2026 Innovation Creation Support Subsidy (Fukushima Tech Create Acceleration Program), awarded to SECOND HEART Inc. and used for the costs of this study


IRB Contact (For public release)

Organization

Fukushima Medical University Ethics Committee

Address

1 Hikarigaoka, Fukushima-city, Fukushima 9601295 JAPAN

Tel

024-547-1825

Email

fmurec@fmu.ac.jp


Secondary IDs

Secondary IDs

YES

Study ID_1

REC2026-117

Org. issuing International ID_1

Fukushima Medical University Ethics Committee

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

福島県立医科大学(福島県)、福島第一病院(福島県)、常磐病院(福島県)、いわき泌尿器科(福島県)、ニュータウン腎・内科クリニック(福島県)、大町病院(福島県)、南相馬市立総合病院(福島県)、相馬中央病院(福島県)、公立相馬総合病院(福島県)


Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 09 Month 25 Day

Date of IRB

2026 Year 11 Month 16 Day

Anticipated trial start date

2026 Year 11 Month 20 Day

Last follow-up date

2027 Year 03 Month 31 Day

Date of closure to data entry

2027 Year 03 Month 31 Day

Date trial data considered complete

2027 Year 03 Month 31 Day

Date analysis concluded

2027 Year 06 Month 30 Day


Other

Other related information

This is a multicenter prospective cohort study. Because the remote screening judgement is generated for this study and returned to the attending physician to inform the referral decision, the study is handled as research involving intervention under the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects in Japan. It involves no invasive procedures. Results will be reported with reference to STARD 2015.


Management information

Registered date

2026 Year 11 Month 17 Day

Last modified on

2026 Year 11 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072859